GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Subscribe To Our Newsletter & Stay Updated
